6 results match your criteria: "Medical and Rehabilitation Center under the Ministry of Health of Russian Federation[Affiliation]"
Article Synopsis
- - In the KEYNOTE-826 study, pembrolizumab combined with chemotherapy significantly boosted overall survival (OS) and progression-free survival (PFS) in patients with advanced cervical cancer, with specific attention to those using bevacizumab.
- - The analysis included 617 patients, with a majority excluded from bevacizumab due to medical reasons; outcomes showed that those receiving pembrolizumab generally had better survival metrics, regardless of bevacizumab use.
- - Patients on pembrolizumab experienced a high rate of severe side effects, with 74% suffering grade ≥3 treatment-related adverse events in the bevacizumab group.
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
JAMA Oncol
February 2024
Gynaecology Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.
Importance: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown.
Objective: To assess efficacy outcomes in patient subgroups of KEYNOTE-826.
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
J Clin Oncol
December 2023
Gynaecology Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.
Article Synopsis
- The KEYNOTE-826 trial tested the effectiveness of pembrolizumab combined with chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer, showing significant improvements in survival rates compared to placebo plus chemotherapy.
- At the final data analysis, median overall survival (OS) for those receiving pembrolizumab was significantly higher than for those on placebo, with results of 28.6 months vs. 16.5 months in one group and similar patterns in others, indicating strong benefits across various patient populations.
- However, there were more grade ≥3 adverse events reported in the pembrolizumab group (82.4%) compared to the placebo group (75.4%), highlighting the need to consider potential side effects alongside treatment
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
April 2023
Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Catholic University of Sacred Heart, Rome, Italy.
Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this Article, we report patient-reported outcomes (PROs) from KEYNOTE-826.
Methods: KEYNOTE-826 is a multicentre, randomised, phase 3 trial in 151 cancer treatment centres in 19 countries.
Aim: To analyze the results of radical surgery for upper GI cancer in patients ≥80 years old.
Material And Methods: For the period November 2010 - June 2015 there were 14 radical operations in elderly (≥80 years) patients with gastric, liver and pancreatic tumors. There were 4 Whipple procedures, 4 total and 2 distal gastrectomies, 1 total pancreatectomy as well as a central liver resection, one laparoscopic 5 segment resection and one 2, 3, 7 segment resection.
Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.
Pancreatology
October 2015
Department of Surgical Oncology, Medical and Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russia. Electronic address:
Background/objectives: Cachexia affects ∼ 80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier.
View Article and Find Full Text PDF